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Sir
We read with great interest the paper by Molinari et al (2009),
recently published in the British Journal of Cancer. The study
compares findings in primary colorectal cancer and paired
metastases in 38 patients, showing differences with respect to
EGFR pathway deregulation, which may imply a different response
to anti-EGFR monoclonal antibodies. As a consequence, the
authors suggest that the analysis of metastatic lesions should be
considered both for patient management and when planning
clinical trials with anti-EGFR drugs.
Although this statement can be considered as a hypothesis
tenable in principle, it seems not to be supported by the results
provided by the study itself, for the following reasons:
(1) Statistical analysis is lacking in terms of study question
definition and sample size calculation and therefore all the
considerations made are not supported by a formal hypothesis
verification;
(2) Comparisons are made in terms of concordance, using the
kappa index, instead of exploiting discrepancies between the
two paired sets of data. However, even looking at concordance
indexes, kappa values were equal to 0.83, 1, 0.73, 1, 0.49 for
KRAS mutational status, BRAF mutational status, PTEN
protein expression, EGFR protein expression and EGFR gene
status, respectively, showing that only for EGFR gene status
the concordance did not reach a ‘good’ value. As no intra-
sample concordance results are available, the question
whether these differences are because of a true discordance
between primary tumour and metastases or rather due to an
intra-sample variability (i.e., variability (a) between different
areas within the same sample because of biological hetero-
geneity (Al-Mulla et al, 1998) or (b) to technical reproduci-
bility) remains unanswered.
(3) Looking at Table 2,
(3.1) for KRAS the data show two patients mutated in primary
tumour whose result became wild type in distant
metastatic sites, whereas one patient wild type in
primary tumour became mutated;
(3.2) only for three patients with PTEN-negative metastases
but positive primary tumours, the finding of non-
response is consistent with biological hypothesis and
other retrospective proof of principles (Loupakis et al,
2009);
(3.3) for BRAF no modification was seen;
(3.4) full concordance was detected for EGFR IHC analysis,
whereas for EGFR gene status the problems related to
the reproducibility are well known.
Even looking at these data in a ‘qualitative’ way, the overall
picture does not seem to suggest a clear trend towards a negative
predictive effect of metastases, and only for PTEN there is some
evidence towards a negative effect.
In the clinical practice, the biopsy of the metastatic lesion could
be an invasive procedure, not free from risks and causes delays in
treatment start, other than understandable anxiety for the patient.
Therefore, costs and advantages should be well balanced. More-
over, it should be considered (1) that the only universally accepted
determinant of resistance to anti-EGFR MoAbs are KRAS
mutations, (2) that post hoc analyses of randomised studies, which
led to the regulatory restriction for anti-EGFR MoAbs to KRAS
wild-type patients were conducted almost exclusively on primary
tumours (Amado et al, 2008; Karapetis et al, 2008) and (3) that
other series greater than the present found a degree of correlation
between primary tumours and related metastases in terms of KRAS
mutational status that does not justify, at present, the clinical need
for biopsies of metastases (Artale et al, 2008; Santini et al, 2008;
Loupakis et al, 2009). Given the retrospective nature of the study,
which exposes the results to selection and verification biases, and
given the small sample size, we do think that no definitive clinical
implication can be driven from this study. Rather, it is important
to stress the need for prospective, properly powered studies, aimed
to evaluate the importance of tumoral sampling at time of
treatment’s start for the molecular prediction of benefit from
anti-EGFR MoAbs, but, at the same time, there are no data for
supporting the need for biopsies of metastases in the routinary
practice.
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